

Date 06/06/2025
Your Ref
Our Ref 10112

Enquiries to Richard Mutch
Extension 35687
Direct Line 0131 465 5687
loth.freedomofinformation@nhs.scot
richard.mutch@nhs.scot

Dear

FREEDOM OF INFORMATION - PRESCRIBING

I write in response to your request for information in relation to prescribing.

Question:

- How many patients were treated in total, regardless of diagnosis, with these medicines in the 3 months between 1st January 2025 to the end of March 2025, or latest 3-months for which data are available?

Answer:

Name of medicine	Number patients treated
1.1 Abiraterone (Zytiga or generic abiraterone)	337
1.2 Apalutamide (Erleada)	7
1.3 Cabazitaxel (Jevtana or generic cabazitaxel)	6
1.4 Darolutamide (Nubeqa)	18
1.5 Enzalutamide (Xtandi)	189
1.6 Talazoparib (Talzenna)	5<
1.7 Docetaxel	82
1.8 Relugolix (Orgovyx, Ryego)	Nil

Question:

- How many patients were treated with these products specifically for **prostate cancer** (ICD-10 code = C61) in the 3 months between 1st January 2025 to the end of March 2025, or latest 3-months for which data are available?

Answer:

Name of medicine	Number patients treated
2.1 Docetaxel for prostate cancer	20
2.2 Olaparib (Lynparza) for prostate cancer	Nil
2.3 Talazoparib (Talzenna) for prostate cancer	Nil
2.4 Relugolix (Orgovyx) for prostate cancer	Nil

Headquarters
Mainpoint
102 West Port
Edinburgh EH3 9DN

Chair Professor John Connaghan CBE
Chief Executive Professor Caroline Hiscox
Lothian NHS Board is the common name of Lothian Health Board

Question:

3. How many patients were treated with the following combinations in the 3 months between 1st January 2025 to the end of March 2025, or latest 3-months for which data are available?

Answer:

Name of medicine	Number patients treated
3.1 Darolutamide (Nubeqa) + Docetaxel + ADT	5<
3.2 Olaparib (Lynparza) + Abiraterone	Nil

Androgen Deprivation Therapy (ADT) = hormonal treatments, such as bicalutamide, leuporelin, triptorelin, degarelix, flutamide

Question:

4. How many patients received the following products for **non-metastatic hormone sensitive prostate cancer** in the 3 months between 1st January 2025 to the end of March 2025, or latest 3-months for which data are available?

Answer:

Name of medicine	Number patients treated
4.1 Abiraterone	116
4.2 Enzalutamide	Nil

To protect the identity of the individuals involved any figure of 5 or less has not been shown in the tables above. Since we do not have their consent to release this data from their records, the information is exempt under section 38(1)(b) of the Freedom of Information (Scotland) Act i.e. to provide it would breach the Data Protection Act (2018).

I hope the information provided helps with your request. I am sorry I cannot help with your request.

If you are unhappy with our response to your request, you do have the right to request us to review it. Your request should be made within 40 working days of receipt of this letter, and we will reply within 20 working days of receipt. If our decision is unchanged following a review and you remain dissatisfied with this, you then have the right to make a formal complaint to the Scottish Information Commissioner within 6 months of receipt of our review response. You can do this by using the Scottish Information Commissioner's Office online appeals service at www.itspublicknowledge.info/Appeal. If you remain dissatisfied with the Commissioner's response you then have the option to appeal to the Court of Session on a point of law.

If you require a review of our decision to be carried out, please write to the FOI Reviewer at the email address at the head of this letter. The review will be undertaken by a Reviewer who was not involved in the original decision-making process.

FOI responses (subject to redaction of personal information) may appear on NHS Lothian's Freedom of Information website at: <https://org.nhsllothian.scot/FOI/Pages/default.aspx>

Yours sincerely

ALISON MACDONALD
Executive Director, Nursing
Cc: Chief Executive